LENZ Therapeutics (LENZ) Equity Ratio (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Equity Ratio data on file, last reported at 0.9 in Q1 2026.

• Quarterly Equity Ratio fell 5.2% year-over-year to 0.9 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.9 (down 5.2% YoY) and the FY2025 annual result came in at 0.93, down 1.93% from the prior year.
• Equity Ratio retreated to 0.9 in Q1 2026 per LENZ's latest filing, from 0.93 in the prior quarter.
• Across five years, Equity Ratio topped out at 0.96 in Q3 2024 and bottomed at 1.32 in Q4 2023.
• The 5-year median for Equity Ratio is 0.93 (2025), against an average of 0.55.
• The widest annual swing landed in 2023, when Equity Ratio tumbled 1654.59%; it then soared 870.69% in 2024.
• Tracing LENZ's Equity Ratio over 5 years: stood at 0.08 in 2022, then plunged by 1654.59% to 1.32 in 2023, then soared by 171.95% to 0.95 in 2024, then declined by 1.93% to 0.93 in 2025, then slipped by 2.71% to 0.9 in 2026.
• Per Business Quant, the three latest LENZ Equity Ratio figures stand at 0.9 (Q1 2026), 0.93 (Q4 2025), and 0.92 (Q3 2025).

Peer Comparison